<DOC>
	<DOCNO>NCT02161510</DOCNO>
	<brief_summary>The objective study identify safe dose MK-2248 participant Hepatitis C Virus ( HCV ) mediate least 3 log10 reduction viral load ( VL ) baseline . It anticipate once-daily administration safe well tolerate dose MK-2248 reduce VL least 3 log10 IU/mL .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics MK-2248 Participants With Hepatitis C ( MK-2248-002 )</brief_title>
	<detailed_description>In Phase 1b study , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) , safety profile MK-2248 HCV-infected participant evaluate follow : Part I assess sequentially ascend MK-2248 dose 200 mg ≤800 mg 4 panel ( A , B , C , D ) . Part II ass sequentially ascend MK-2248 dose 200 mg ≤800 mg 4 panel ( E , F , G , H ) . Part III ass sequentially ascend MK-2248 dos range ≤800 mg 2 panel ( I J ) . The potential relationship plasma MK-2248 level VL reduction determine .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>clinical diagnosis chronic HCV define positive serology HCV positive HCV RNA least 6 month detectable HCV RNA peripheral blood ≥10^5 IU/mL screen Body Mass Index ( BMI ) ≥18 &lt; 37 kg/m^2 good health HCV infection normal laboratory value history clinically significant stably control endocrine , gastrointestinal , cardiovascular , hematological , hepatic ( except HCV infection ) , immunological , renal , respiratory , genitourinary , major neurological abnormality disease history cancer adequately treat nonmelanomatous skin carcinoma , malignancy successfully treat ≥10 year prior recurrence , cancer unlikely sustain recurrence duration trial history significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food positive hepatitis B surface antigen human immunodeficiency virus major surgery lose 1 unit blood within 4 week prior screen QTc interval ≥470 msec ( male ) ≥480 msec ( female ) receive prior treatment HCV inhibitor clinical laboratory evidence decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>